<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633811</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300006133</org_study_id>
    <nct_id>NCT04633811</nct_id>
  </id_info>
  <brief_title>Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers</brief_title>
  <official_title>Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to&#xD;
      reduced contribution of endogenous oxalate synthesis to the urinary oxalate pool in obese&#xD;
      calcium oxalate stone formers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of 24 hour urinary oxalate excretion</measure>
    <time_frame>Day 4</time_frame>
    <description>Subjects will ingest a controlled diet low in oxalate and collect 2 x 24-hour urines before and after the Optifast VLCD Program. The utilization of a low oxalate diet allows assessment of the change in contribution of endogenous oxalate synthesis to the urinary oxalate pool.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Controlled Diet and Weight Loss Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume a low oxalate diet with blood and urine collections to establish baseline levels before undergoing a weight loss program with Optifast VLCD products. After completing the weight loss program, subjects will once again consume a low oxalate diet with blood and urine collections to observe any changes that may have occurred due to the weight loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low Oxalate Diet</intervention_name>
    <description>Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 7 days</description>
    <arm_group_label>Controlled Diet and Weight Loss Program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral load of oxalate and sucralose</intervention_name>
    <description>Subjects will ingest 4 mmoles of sodium oxalate, which includes 50mg carbon-13 oxalate, and 5 grams of sucralose on the last day of the 7-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively</description>
    <arm_group_label>Controlled Diet and Weight Loss Program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Optifast VLCD Program</intervention_name>
    <description>Subjects will go on a 12-week Intestive level Optifast VLCD weight loss program</description>
    <arm_group_label>Controlled Diet and Weight Loss Program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Optifast VLCD Transition Phase</intervention_name>
    <description>After completion of the 12-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 2 weeks.</description>
    <arm_group_label>Controlled Diet and Weight Loss Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Calcium Oxalate Stone Formers (CaOx SF): last stone composition greater than 50% CaOx&#xD;
&#xD;
          -  Last stone passage or removal greater than 3 months prior to screening&#xD;
&#xD;
          -  Body Mass Index (BMI) between 30 and 45 kg/m2&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
          -  Normal fasting serum electrolytes on comprehensive metabolic profile&#xD;
&#xD;
          -  24-hour urine collection with creatinine within 20% of gender appropriate (mg creat/kg&#xD;
             body weight) and consistent between collections (within 20% of each other)&#xD;
&#xD;
          -  Willing to ingest menus prepared at the University of Alabama and University of Texas&#xD;
             Southwestern Clinical Research Units&#xD;
&#xD;
          -  Willing to consume the Optifast VLCD diet&#xD;
&#xD;
          -  No food allergies/intolerance to any of the foods in study menus&#xD;
&#xD;
          -  Willing to avoid vigorous exercise during eucaloric, low-oxalate dietary phase&#xD;
&#xD;
          -  Willing to stop use of weight-loss medications&#xD;
&#xD;
          -  Willing to stop for 14 days before and during study: medications for stone prevention&#xD;
             including diuretics, potassium citrate, allopurinol, febuxostat, and calcium,&#xD;
             nutritional, or herbal supplements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal colic in the past 3 months&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min/1.73m2&#xD;
&#xD;
          -  History of type 2 diabetes or screening hgb A1c greater than or equal to 6.5%&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Mental/medical condition likely to impede study completion&#xD;
&#xD;
          -  Fertility issues, current/planned pregnancy or breastfeeding in coming 6 months&#xD;
&#xD;
          -  Febrile illness including flu/common cold/COVID-19 within 21 days of study start&#xD;
&#xD;
          -  Primary or enteric hyperoxaluria&#xD;
&#xD;
          -  Gastrointestinal disorder or surgery that impacts oxalate transport&#xD;
&#xD;
          -  Cirrhosis, pancreatic or biliary disorder, porphyria, gout&#xD;
&#xD;
          -  Malignancy treated within the past 12 months&#xD;
&#xD;
          -  Nephrotic syndrome, neurogenic bladder, urinary diversion&#xD;
&#xD;
          -  History of primary hyperparathyroidism, cystinuria, renal tubular acidosis,&#xD;
             sarcoidosis, cystic fibrosis&#xD;
&#xD;
          -  Uncontrolled hypertension, myocardial infarction in past 6 months, unstable angina,&#xD;
             congestive heart failure&#xD;
&#xD;
          -  Antibiotic use in last 6 months&#xD;
&#xD;
          -  Medications: Topiramate, acetazolamide, zonisamide, diuretics, SGLT2-inhibitors,&#xD;
             immunosuppressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Assimos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Demond Wiley</last_name>
    <phone>2059343671</phone>
    <email>kidneystone@uabmc.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Dean Assimos, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

